ArticleDrug design, development and therapy2026
Advancing Daptomycin Precision Dosing Through Evaluation of Published Population Pharmacokinetic Models and Development of a Dosing Tool.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Daptomycin is an important antibiotic against multidrug-resistant Gram-positive infections, but its wide interindividual variability and narrow therapeutic window pose challenges for optimal dosing. Population pharmacokinetic (PopPK) models provide a quantitative framework for precision dosing, yet a systematic evaluation of existing models and their clinical application method remains lacking. Methods: Model structures, demographic characteristics, and covariate effects were systematically summarized from previously published papers. Predictive performance was compared through simulations in virtual populations with varying renal function. Monte Carlo simulations were performed to evaluate the probability of target attainment (PTA; AUC24 Results: Eighteen PopPK studies were included in this analysis. Renal function was the most frequently identified covariate influencing clearance. Model comparisons revealed variability in predicting exposure and PTA. Simulations indicated that patients with impaired renal function face a higher risk of exceeding the toxicity threshold, even at moderate doses. The developed Shiny-based tool enables real-time estimation of AUC and Cmin, integration of therapeutic drug monitoring data, and individualized dose adjustment. Conclusion: This study provides a comprehensive evaluation of daptomycin PopPK models and translates these findings into a practical precision dosing tool. This work enhances understanding of interindividual variability of daptomycin and offers clinicians a scientifically grounded resource to optimize daptomycin therapy in diverse patient populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.